Fulcrum Therapeutics FULC Stock
Fulcrum Therapeutics Price Chart
Fulcrum Therapeutics FULC Financial and Trading Overview
| Fulcrum Therapeutics stock price | 6.9 USD |
| Previous Close | 3.02 USD |
| Open | 3 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1800 |
| Day's Range | 2.94 - 3.07 USD |
| 52 Week Range | 2.25 - 15 USD |
| Volume | 478.61K USD |
| Avg. Volume | 833.37K USD |
| Market Cap | 187.75M USD |
| Beta (5Y Monthly) | 2.107836 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.44 USD |
FULC Valuation Measures
| Enterprise Value | -98527840 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.6 |
| PEG Ratio (5 yr expected) | -0.27 |
| Price/Sales (ttm) | 46.414677 |
| Price/Book (mrq) | 0.6337294 |
| Enterprise Value/Revenue | -24.358 |
| Enterprise Value/EBITDA | 0.883 |
Trading Information
Fulcrum Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.107836 |
| 52-Week Change | -33.76% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 15 USD |
| 52 Week Low | 2.25 USD |
| 50-Day Moving Average | 2.9 USD |
| 200-Day Moving Average | 6.53 USD |
FULC Share Statistics
| Avg. Volume (3 month) | 833.37K USD |
| Avg. Daily Volume (10-Days) | 518.26K USD |
| Shares Outstanding | 61.76M |
| Float | 38.54M |
| Short Ratio | 5.45 |
| % Held by Insiders | 4.82% |
| % Held by Institutions | 90.43% |
| Shares Short | 4.13M |
| Short % of Float | 8.26% |
| Short % of Shares Outstanding | 6.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2820.17% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.34% |
| Return on Equity (ttm) | -44.79% |
Income Statement
| Revenue (ttm) | 4.05M USD |
| Revenue Per Share (ttm) | 0.08 USD |
| Quarterly Revenue Growth (yoy) | -88.59% |
| Gross Profit (ttm) | -70440000 USD |
| EBITDA | -111632000 USD |
| Net Income Avi to Common (ttm) | -108722000 USD |
| Diluted EPS (ttm) | -2.22 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 297.84M USD |
| Total Cash Per Share (mrq) | 4.82 USD |
| Total Debt (mrq) | 12.8M USD |
| Total Debt/Equity (mrq) | 4.32 USD |
| Current Ratio (mrq) | 21.02 |
| Book Value Per Share (mrq) | 4.797 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -99060000 USD |
| Levered Free Cash Flow (ttm) | -61141500 USD |
Profile of Fulcrum Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 26 Landsdowne Street |
| ZIP | 02139 |
| Phone | 617 651 8851 |
| Website | https://www.fulcrumtx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 89 |
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Fulcrum Therapeutics Stock
What is a current FULC stock price?
Fulcrum Therapeutics FULC stock price today per share is 6.9 USD.
How to purchase Fulcrum Therapeutics stock?
You can buy FULC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fulcrum Therapeutics?
The stock symbol or ticker of Fulcrum Therapeutics is FULC.
Which industry does the Fulcrum Therapeutics company belong to?
The Fulcrum Therapeutics industry is Biotechnology.
How many shares does Fulcrum Therapeutics have in circulation?
The max supply of Fulcrum Therapeutics shares is 53.98M.
What is Fulcrum Therapeutics Price to Earnings Ratio (PE Ratio)?
Fulcrum Therapeutics PE Ratio is now.
What was Fulcrum Therapeutics earnings per share over the trailing 12 months (TTM)?
Fulcrum Therapeutics EPS is -0.01 USD over the trailing 12 months.
Which sector does the Fulcrum Therapeutics company belong to?
The Fulcrum Therapeutics sector is Healthcare.
Fulcrum Therapeutics FULC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19100.94 USD — |
-0.51
|
7.61B USD — | 19084.38 USD — | 19276.83 USD — | — - | 7.61B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1954.17 USD — |
-0.77
|
— — | 1953.48 USD — | 1971.36 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4086.22 USD — |
-0.88
|
— — | 4081.49 USD — | 4131.86 USD — | — - | — — |
| Nasdaq Health Care IXHC | 941.34 USD — |
-0.51
|
— — | 940.07 USD — | 947.81 USD — | — - | — — |
- {{ link.label }} {{link}}